POZEN Logo
Print Page   Close Window

Press Release

POZEN CEO to Present at Friedman, Billings, Ramsey & Co. Inc., 7th Annual Technology & Growth Investor Conference

CHAPEL HILL, N.C.--(BUSINESS WIRE)--May 22, 2003--POZEN Inc. (Nasdaq: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will be speaking to investors at the Friedman, Billings, Ramsey & Co. Inc., 7th Annual Technology & Growth Investor Conference on Thursday, May 29, at 8:40 a.m. Eastern Time. Dr. Plachetka will provide an overview of POZEN's business.

The presentation will be webcast live and archived on POZEN's home page at www.pozen.com.

POZEN is a pharmaceutical company developing therapeutic advancements in a cost effective manner. Since its inception, POZEN has developed the largest and most advanced product pipeline in the field of migraine. Product development efforts are focused on diseases with unmet needs and where POZEN can improve efficacy, safety, and/or patient convenience. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN." For detailed company information, see POZEN's website: www.pozen.com.

CONTACT:
POZEN Inc.
Matt Czajkowski
Chief Financial Officer
919-913-1030
or
Lisa Barthelemy
Director, Investor Relations
919-913-1044